Dyax’s Acute HAE Candidate Faces Efficacy And Risk Hurdles At Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is presenting a risk management plan addressing hypersensitivity and anaphylaxis, but efficacy results for Kalbitor (ecallantide) will also be a key discussion topic.